Tag Archives: PhRMA
By Ben Comer | Published: February 13, 2013
During his fifth State of the Union address, President Obama struck many familiar chords – including a line about ending certain subsidies to pharmaceutical companies – and emphasized, repeatedly, the need to get things done on the policy front. Will the sequestration drum beat goad members of the 113th Congress onto the dance floor?
By Jill Wechsler | Published: January 21, 2013
Biopharmaceutical companies are touting their huge investment in R&D, which has filled the drug pipeline with more potential first-in-class medicines, including orphan drugs, personalized medicines and new therapies based on novel scientific strategies. A report by the Analysis Group for the Pharmaceutical Research and Manufacturers of America (PhRMA) documents more than 5,000 new medicines in […]
By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
By Ben Comer | Published: September 7, 2011
A trade group representing the largest pharmacy benefits managers (PBMs) has proposed a way to trim $100 billion in government costs for prescription drugs over 10 years. To the pharmaceutical industry, that trim might look more like a beheading.
By Ben Comer | Published: August 16, 2011
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.